84467-54-9

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)-DIDESMETHYLSIBUTRAMINE is used as an appetite suppressant for weight loss management. It functions by decreasing calorie intake and increasing energy expenditure, making it a potential candidate for obesity treatment and weight management programs.
Used in Research and Development:
(+/-)-DIDESMETHYLSIBUTRAMINE is used as a research compound to study the effects of serotonin and noradrenaline reuptake inhibition on appetite regulation and energy metabolism. This helps in understanding the underlying mechanisms of weight loss and the development of new therapeutic agents for obesity and related metabolic disorders.

InChI:InChI=1/C15H22ClN/c1-11(2)10-14(17)15(8-3-9-15)12-4-6-13(16)7-5-12/h4-7,11,14H,3,8-10,17H2,1-2H3

Upstream product

• 78-77-3 Isobutyl bromide 
• 28049-61-8 1-(4-chlorophenyl)cyclobutanecarbonitrile 
• 84467-85-6 N-{1-[1-(4-chlorophenylcyclobutyl)]-3-methylbuty}formamide 
• 421558-88-5 1-[1-(4-chloro-phenyl)-cyclobutyl]-3-methyl-butylideneamine 
• 106079-12-3 1-(4-chlorophenyl)-cyclobutanecarboxaldehyde 
• 920-36-5 (2-methylpropyl)lithium 
• 858645-29-1 (R)-N-(1-(4-chlorophenyl)cyclobutanemethylene)-t-butanesulfinamide 

Downstream Products

• 84467-85-6 N-{1-[1-(4-chlorophenylcyclobutyl)]-3-methylbuty}formamide 
• 229639-57-0 (S)-(-)-1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutylamine 
• 259729-93-6 (R)-DDMS-D-TA 
• 154752-44-0 (R)-(+)-N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine 

Relevant academic research and scientific papers

COMPOSITIONS, SYNTHESIS, AND METHODS OF USING PHENYLCYCLOALKYLMETHYLAMINE DERIVATIVES

The present invention provides novel phenylcycloalkylmethylamme derivatives, and methods of preparing phenylcycloalkylmethylamme derivatives. The present invention also provides methods of using phenylcycloalkylmethylamme derivatives and compositions of phenylcycloalkylmethylamme derivatives. The pharmaceutical compositions of the compounds of the present invention can be used for treating and/or preventing obesity and obesity related co- morbid indications and depression and depression related co-morbid indications.

Compositions, Synthesis, and Methods of Using Cycloalkylmethylamine Derivatives

The present invention provides novel cycloalkylmethylamine derivatives, and methods of preparing cycloalkylmethylamine derivatives. The present invention also provides methods of using cycloalkylmethylamine derivatives and compositions of cycloalkylmethylamine derivatives. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications and depression and depression related co-morbid indications.

PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARATION PROCESSES AND USES THEREOF

Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl,

PHENYLCYCLOBUTYLAMIDE DERIVATIVES AND THEIR STEREOISOMERS, THE PREPARING PROCESSES AND THE USES THEREOF

Phenylcyclobutylamide derivatives and their optical isomers, the preparing processes and the uses thereof, which includes the compounds of formula (I), their pure stereoisomers and their pharmaceutically acceptable salts. In formula (I), R is H, formacyl,

Highly enantioselective catalytic asymmetric synthesis of a (R)-sibutramin precursor

The first highly enantioselective, catalytic asymmetric synthesis of di-des-methylsibutramine 3 is described. Dienamide 10, prepared by acetic acid anhydride quenching of the condensation product of nitrile 4 with a methallyl magnesium chloride, proved to

SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF CYCLOALKYLMETHYLAMINES

The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.

A new and direct asymmetric synthesis of a hindered chiral amine via a novel sulfinate ketimine derived from N-tosyl-1,2,3-oxathiazolidme-2-oxide: Practical asymmetric synthesis of (R)-sibutramine

A novel and direct approach for the asymmetric synthesis of (R)-sibutramine via chiral amine 5 using N-tosyl-1,2,3-oxathiazolidine-2-oxide (13) as a recyclable chiral auxiliary is described. Chiral sulfinate imine 16e was obtained by treatment of 13e with

DOPAMINE-AGONIST COMBINATION THERAPY FOR IMPROVING SLEEP QUALITY

The present invention generally to pharmaceutical compositions comprising a dopamine agonist and sedative agent. In a preferred embodiment, the dopamine agonist is optically pure (S)-didesmethylsibutramine. In a preferred embodiment, the sedative agent is

USE OF (S)-DIDESMETHYLSIBUTRAMINEFOR TREATING, PREVENTING AND MANAGING A SLEEP DISORDER

This invention relates, in part, to methods of treating, preventing and/or managing a sleep disorder using enantiomerically pure (S)-didesmethylsibutramine, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or prodrug thereof. Specific me

A method of manufacturing an amine stereoisomerically

This invention provides intermediates useful in a method of preparing amine stereoisomers. It also provides a method of preparing sulfoxide and sulfinylamine stereoisomers using certain of the intermediates.